期刊文献+

新疆维吾尔族冠心病患者阿司匹林抵抗的临床分析 被引量:4

原文传递
导出
摘要 目的探讨新疆维吾尔族冠心病患者中阿司匹林抵抗(AR)临床特点。方法选取110例维吾尔族冠心病住院患者,服用阿司匹林100mg/d,连服7d,分别以二磷酸腺苷(ADP)和花生四烯酸(AA)为诱导剂检测患者的血小板聚集率,观察阿司匹林抵抗(AR)与丰抵抗(ASR)的临床特点:结果入选患者中阿司匹林抵抗发生率为5.5%(6/110),阿司匹林半抵抗(ASR)发生率为24.5%(27/110)。AR或ASR与阿司匹林敏感者(AS)相比:老年患者[(63.82±6.78)岁比(59.04±4.35)岁,P〈0.05)]与女性患者较多(60.6%比38.9%,P〈0.05);低密度脂蛋白浓度较高(P〈0.01);与高血压、糖尿病、血小板计数无关。结论在服用阿司匹林的新疆维吾尔族冠心病患者中5.5%出现AR,说明部分服用阿司匹林治疗的患者血小板聚集功能未被有效抑制,存在AR现象、
出处 《中国医师杂志》 CAS 2009年第12期1724-1725,共2页 Journal of Chinese Physician
  • 相关文献

参考文献8

  • 1Eric HA, Jossplt L. Aspirin. Circulation, 2000,101:1206-1209.
  • 2Gum PA ,Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cadiol, 2001,88:230-235.
  • 3Antiplatelet Trialists' Collaborative ized trials of antiplatelet therapy-Ⅰ : Collaborative overview of random- Prevention of death, myocardial infarction , and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med, 1994,308:81-106.
  • 4Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004,126(3 Suppl ):234-264.
  • 5Christiaens L, Macchi L, Herpin D, et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res,2003,108 : 115-117.
  • 6Christiacns L, Macchi L, Herpin D, et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary disease. Thromb Res, 2003,108 : 115-119.
  • 7Maribeth F, Ivana V. Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMI,2003 ,326 :82-83.
  • 8Hani J, Deepak L B, Roberto C, et al. Aapirin and clopidogrel in acute coronary syndromes: therapeutic: insights from the CURE study. Arch Inter Med, 2003, 163 : 1145-1153.

同被引文献35

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部